This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Neoadjuvant NSCLC

THE FIRST NEOADJUVANT IMMUNOTHERAPY IN NSCLC

View indication details

  • OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence (stage II-IIIA disease according to the 7th edition AJCC/UICC) in adult patients whose tumours have PD-L1 expression ≥ 1%.
Expert opinion

Immunotherapy in
the resectable NSCLC setting

Educational meeting hosted by Prof Van Schil

CheckMate 816 study results

ECLIPSE webinar series for continuous I-O learning via live peer-to-peer clinical practice exchanges

Product information

OPDIVO + chemotherapy
in neoadjuvant NSCLC

Dosing scheme
OPDIVO
in neoadjuvant NSCLC

Practical user guide
based on OPDIVO SmPC

PD-L1 testing
overview for OPDIVO

Patient & nurse materials

Patient brochure
with practical information
on immunotherapy

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient alert card
OPDIVO

Useful links

NSCLC, non small cell lung cancer; irAE(s), immune-related adverse event(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.